Myelodysplastic Syndrome
Showing NaN - NaN of 117
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Worldwide (FT-2102 (olutasidenib),
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- FT-2102 (olutasidenib)
- +2 more
-
Los Angeles, California
- +59 more
Mar 2, 2022
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of
Active, not recruiting
- Acute Myeloid Leukemia With Multilineage Dysplasia
- +6 more
- Azacitidine
- Glutaminase Inhibitor CB-839
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +12 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +2 more
Feb 17, 2022
Hematopoietic and Lymphoid Cell Tumor, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome Trial in Houston
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +13 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Houston, TexasM D Anderson Cancer Center
Feb 8, 2022
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Tumor Trial in United States (APR-246, Azacitidine)
Completed
- Myelodysplastic Syndrome
- +3 more
-
Tampa, Florida
- +5 more
Jan 14, 2022
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell
Completed
- Acute Lymphoblastic Leukemia in Remission
- +6 more
- Allogeneic Bone Marrow Transplantation
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 15, 2021
Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Houston (Anti-Thymocyte Globulin,
Recruiting
- Aplastic Anemia
- +3 more
- Anti-Thymocyte Globulin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Dec 1, 2021
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Neutropenia Trial in Houston (Isavuconazole)
Completed
- Acute Myeloid Leukemia
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 6, 2021
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in United States (Milademetan, AZA)
Terminated
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
-
Duarte, California
- +4 more
Sep 14, 2021
Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (Nivolumab, Idarubicin, Cytarabine)
Completed
- Leukemia
- +2 more
- Nivolumab
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 9, 2021
Myelodysplastic Syndrome, Iron Overload Trial in Canada, United States (Deferasirox)
Completed
- Myelodysplastic Syndrome
- Iron Overload
-
Birmingham, Alabama
- +47 more
Jul 21, 2021
Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Tumor, Myelodysplastic Syndrome Trial in United States (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- Azacitidine
- +2 more
-
Boston, Massachusetts
- +3 more
Jun 30, 2021
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in France, United States (oral
Completed
- Myelodysplastic Syndrome
- +2 more
- oral rigosertib
- Azacitidine
-
Gilbert, Arizona
- +12 more
Jun 15, 2021
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial in Philadelphia, Houston (Decitabine,
Completed
- Acute Myeloid Leukemia
- +2 more
- Decitabine
- +2 more
-
Philadelphia, Pennsylvania
- +1 more
May 18, 2021
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia Trial in Houston (Clofarabine, Busulfan, Fludarabine)
Completed
- Acute Myeloid Leukemia
- +2 more
- Clofarabine
- +5 more
-
Houston, TexasUT MD Anderson Cancer Center
Jan 6, 2021
Myelodysplastic Syndrome, Leukemia, Acute Myeloid Leukemia Trial in Houston (Busulfan, Fludarabine)
Completed
- Myelodysplastic Syndrome
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 12, 2021
Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome Trial in Houston (drug, biological, other)
Recruiting
- Leukemia
- +2 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 13, 2021
Myelodysplastic Syndrome, MDS Trial in Canada, United States (ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727
Completed
- Myelodysplastic Syndrome
- MDS
- ASTX727 Dose Escalation
- +2 more
-
Phoenix, Arizona
- +16 more
Dec 1, 2020
Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Houston (TXA127 300 mcg/kg/day,
Terminated
- Double Cord Blood Transplant
- +8 more
- TXA127 300 mcg/kg/day
- TXA127 1000 mcg/kg/day
-
Houston, TexasMD Anderson Cancer Center
Dec 7, 2020
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia Trial in Houston (Clofarabine 40mg/m^2, Idarubicin
Completed
- Acute Myeloid Leukemia
- +2 more
- Clofarabine 40mg/m^2
- +5 more
-
Houston, TexasUT MD Anderson Cancer Center
Dec 3, 2020
Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Houston (Fludarabine monophosphate, Busulfan, Stem Cell
Active, not recruiting
- Leukemia
- +9 more
- Fludarabine monophosphate
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 2, 2020
Hematological Malignancies, Myelodysplastic Syndrome, Leukemia Trial in Houston (Mycophenolate Mofetil (MMF), Thymoglobulin,
Terminated
- Hematological Malignancies
- +3 more
- Mycophenolate Mofetil (MMF)
- +3 more
-
Houston, TexasUT MD Anderson Cancer Center
Sep 1, 2020
Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001 (varying
Withdrawn
- Chronic Myelogenous Leukemia, Ph1-Positive
- +2 more
- BP1001 (varying dose)
- +2 more
-
Houston, TexasThe University of Texas M.D. Anderson Cancer Center
May 26, 2020
Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001, BP1001
Completed
- Recurrent Adult Acute Myeloid Leukemia
- +3 more
- BP1001
- BP1001 in combination with LDAC
-
Houston, TexasM. D. Anderson Cancer Center
May 26, 2020